Recent research have focused on the overlap of GLP-1|GIP|glucagon receptor agonist therapies and dopamine communication. While GIP agonists are increasingly employed for treating type 2 T2DM, their unexpected effects on reinforcement circuits, specifically mediated by dopamine systems, are gaining substantial focus. This article presents a summa… Read More